A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination With Fludarabine and Cytarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Trial Profile

A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination With Fludarabine and Cytarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs Panobinostat (Primary) ; Cytarabine; Fludarabine; Folinic acid; Folinic acid
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Apr 2017 Planned End Date changed from 1 Apr 2018 to 31 Aug 2018.
    • 06 Apr 2017 Planned primary completion date changed from 1 Apr 2018 to 31 Aug 2018.
    • 15 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top